Concepedia

Author

Anne Lennard

Royal Victoria Infirmary

Also Known As

A L Lennard, A Lennard, A. L. Lennard, A. LENNARD, A. Lennard, A.L Lennard, A.L. Lennard, Anne L Lennard, Anne L. Lennard, Anne Lennard

86

Publications

4.4K

Citations

27

H-Index

49

Concepts

All Affiliations

Royal Victoria InfirmaryNewcastle UniversityFreeman HospitalCharles UniversityHammersmith Hospital
AL

About

Anne Lennard is an author at Royal Victoria Infirmary specializing in medicine, oncology, and pathology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

18

22

1.4K

2

Health Sciences

6

6

261

3

Engineering

1

1

37

4

Public Health

1

1

99

5

Biostatistics

1

1

99

Anne Lennard

×

38

Publications

3.2K

Citations

24

H-Index

YearCitations

Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial

Steven M. Horwitz, Owen A. O’Connor, Barbara Pro,

The Lancet

2018

707

Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial

Laurie H. Sehn, Neil Chua, Greg Dueck,

The Lancet Oncology

2016

336

Primary diffuse large B-cell lymphoma of the breast: prognostic factors and outcomes of a study by the International Extranodal Lymphoma Study Group

G.B. Ryan, Giovanni Martinelli, Marion Kuper‐Hommel,

Annals of Oncology

2007

249

Evaluation of enteropathy-associated T-cell lymphoma comparing standard therapies with a novel regimen including autologous stem cell transplantation

Michal Sieniawski, Nithia Angamuthu, Kathryn Boyd,

Blood

2010

227

Overall Survival Benefit in Patients With Rituximab-Refractory Indolent Non-Hodgkin Lymphoma Who Received Obinutuzumab Plus Bendamustine Induction and Obinutuzumab Maintenance in the GADOLIN Study

Bruce D. Cheson, Neil Chua, Greg Dueck,

Journal of Clinical Oncology

2018

162

Randomized Phase III Study of Alisertib or Investigator’s Choice (Selected Single Agent) in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma

Owen A. O’Connor, Muhıt Özcan, Eric D. Jacobsen,

Journal of Clinical Oncology

2019

143

Posttransplantation imatinib as a strategy to postpone the requirement for immunotherapy in patients undergoing reduced-intensity allografts for chronic myeloid leukemia

Eduardo Olavarría, Shamyla Siddique, Sharon Avery,

Blood

2007

109

A numerical prognostic index for clinical use in identification of poor-risk patients with Hodgkin's disease at diagnosis

Stephen J. Proctor, Penny Taylor, Peter T. Donnan,

European Journal of Cancer and Clinical Oncology

1991

99

Long-term outcome for gastric marginal zone lymphoma treated with radiotherapy: a retrospective, multi-centre, International Extranodal Lymphoma Study Group study

A. Wirth, Mary Gospodarowicz, Berthe M.P. Aleman,

Annals of Oncology

2013

96

Breast implant associated anaplastic large cell lymphoma: The UK experience. Recommendations on its management and implications for informed consent

L Johnson, J.M. O’Donoghue, N.R. McLean,

European Journal of Surgical Oncology

2017

94

Page 1